Atyr PHARMA (NASDAQ:ATYR) Given “Buy” Rating at HC Wainwright

Atyr PHARMA (NASDAQ:ATYR)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $35.00 price target on the stock.

A number of other research analysts have also recently commented on the stock. Wells Fargo & Company began coverage on shares of Atyr PHARMA in a research note on Friday, October 4th. They set an “overweight” rating and a $17.00 price target for the company. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $16.00 price target on shares of Atyr PHARMA in a research note on Wednesday, August 14th. Finally, Jefferies Financial Group began coverage on Atyr PHARMA in a research report on Thursday, September 5th. They issued a “buy” rating and a $9.00 price target on the stock.

Atyr PHARMA Stock Down 4.5 %

Atyr PHARMA stock traded down $0.16 during mid-day trading on Tuesday, reaching $3.37. The company had a trading volume of 400,679 shares, compared to its average volume of 585,974. The company has a current ratio of 5.41, a quick ratio of 5.41 and a debt-to-equity ratio of 0.02. The stock has a market cap of $282.88 million, a price-to-earnings ratio of -3.59 and a beta of 1.07. The stock’s 50 day simple moving average is $2.95. Atyr PHARMA has a 52 week low of $1.14 and a 52 week high of $3.80.

Atyr PHARMA (NASDAQ:ATYR) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.01). On average, analysts predict that Atyr PHARMA will post -0.89 earnings per share for the current fiscal year.

About Atyr PHARMA

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.